Oct 29 (Reuters) - Eli Lilly ( LLY ) said on Wednesday

it is partnering with Walmart ( WMT ) to expand access to

Lilly's weight-loss drug Zepbound, which will be offered for

pick-up at Walmart ( WMT ) pharmacies nationwide by mid-November.

Lilly and rival Novo Nordisk started offering

vials at discounted prices on their respective websites to

expand access and stave off competition from compounded versions

or cheaper copies of their weight-loss drugs.

Lilly has been providing all approved doses of Zepbound to

cash-paying customers through its website LillyDirect, which was

launched last year.

The drugmaker said Walmart ( WMT ) pharmacies will offer Zepbound

single-dose vials in all approved strengths, with the lowest

dose starting at $349 per month with self-pay.